Introduction
Traditional approaches to identifying fetal chromosomal abnormalities, such as Down or Edwards syndrome, include maternal serum tests and fetal nuchal translucency (NT) assessments using ultrasound scanning [1] . Maternal serum tests include a double marker test measuring two markers of β-human chorionic gonadotropin (hCG) and pregnancyassociated plasma protein A; a triple marker test measuring three markers of hCG, alpha-fetoprotein (AFP), and unconjugated estriol (uE3) in the second trimester; and a quadruple marker test measuring four markers of hCG, AFP, uE3, and inhibin A [2, 3] . Recently, an integrated screening test that combines the results sequencing (MPS) have been used to identify fetal cffDNA in maternal blood, differentiate fetal DNA from maternal DNA, and detect fetal chromosomal abnormalities [7] [8] [9] [10] [11] [12] . These NIPT methods are promising, in that they are safe and show good clinical performance with sensitivities up to 100% and specificities up to 99% [13] . Currently, in the United States, Sequenom, Verinata Health, Ariosa Diagnostics, and Natera offer NIPT services [14, 15] . In Korea, Momguard, an independent NIPT protocol, was developed using a random massively parallel shotgun sequencing method [16] . A large-scale blind evaluation of the assay is currently in progress in multiple Korean cohorts [16] . In this study, we preliminarily evaluated the performance of Momguard by analyzing 'screen positive' results in samples from the independent Korean cohort.
Materials and Methods

Study design
This preliminary study is based on data collected by LabGenomics Clinical Laboratory (Seongnam, Korea) in 2015. We obtained approval for the study from our institutional review board (2013-03) and included only the participants who gave written informed consent. This study included pregnant women who were reported as being at high risk for fetal anomalies based on the Momguard test and those who underwent an amniocentesis to confirm fetal karyotype.
Sample collection
Maternal blood samples were collected in Cell-Free DNA BCT tubes (Streck, Omaha, NE, USA) and delivered to the laboratory within 24 hr of collection. To isolate plasma from the maternal blood, a two-step centrifugation process was applied, with centrifugation at 1,600 ×g for 10 min and then at 16,000 ×g for 10 min at 4 o C. In 1.5-mL tubes labeled with distinct sample codes, the isolated plasma was distributed into 1-mL aliquots. Aliquots were frozen at -80 o C until they were analyzed.
Cell-free DNA (cfDNA) extraction and sequencing
To isolate cfDNA from 2 mL of maternal plasma, a QIAmp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) was employed. The extracted cfDNA was eluted in 40 µL of AVE buffer (Qiagen). According to the Momguard library preparation protocol, the cfDNA library was prepared and evaluated using a PicoGreen assay and 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Resulting libraries were sequenced using a NextSeq 500 instrument (Illumina Inc., San Diego, CA, USA) or Ion Torrent (Life Technology, Waltham, MA, USA).
Sequencing data analysis
Sequencing data were analyzed with an in-house bioinformatics pipeline called GeneBro. In brief, paired-end sequencing reads were binned according to the index sequence and mapped to the reference human genome sequence (hg19). The tool of Burrows-Wheeler Alignment was used to align the sequences to the human genome, and the uniquely aligned reads were used to calculate the statistical values of euploid pregnancies. By applying an ensemble algorithm to perform a similarity analysis based on features such as fetal fraction, gestational age, or guanine-cytosine (GC) content, test samples were evaluated for the risk of fetal aneuploidy.
Results
Demographic characteristics
The Momguard test identified 38 'screen positive' results, including samples that were positive for fetal trisomy (T) 21 (n=31), T18 (n=4), and T13 (n=3). The median maternal age of these subjects was 35 years and gestational age was 14.5 weeks (Table 1) . When classified by specific aneuploidy, the median maternal ages associated with T13 cases were lower than those associated with T18 or T21 cases. In contrast, the median gestational ages associated with T13 cases were the highest of the three at 16.4 weeks. Considering the small number of T13 cases (n=3), this may not be statistically meaningful.
Sequencing and karyotyping results
Among the 38 'screen positive' results from the Momguard test, 30 cases, including those associated with T21 (n=24), T18 (n=3), and T13 (n=3) cases, had karyotyping results available during the study period (Table 2) . For all T18 and T13 cases, 
Discussion
The Momguard test is the first NIPT in Korea developed by original technology called GeneBro. It applies an ensemble algorithm to perform a similarity analysis based on features such as fetal fraction, gestational age, or GC content. The performance of the Momguard test has been assessed in the previous, prospective cohort study carried out in multiple centers, including the Asan Medical Center [16] . The authors showed that the Momguard test is highly accurate in detecting T21 and T18 cases. Due to its rarity, only one T13 sample was identified in that study: it was determined 'intermediate risk' by the Momguard test and was subsequently verified by CVS.
In this study, we attempted to confirm the reliability of the Momguard test with independent samples. We planned to evaluate all 38 'screen positive' results, including those indicating trisomy cases. However, due to time constraints, karyotyping results were not available for all of the samples that tested positive by Momguard. Although the results presented here are limited to a preliminary analysis that verified 30 Momguard results, including those indicating a trisomy, additional results will be available in the near future. Since the evaluation is ongoing, whenever 'screen positive' data becomes available, it will be verified and reported.
Among the 30 cases with both Momguard and karyotyping results, only one case was identified as being at intermediate risk for T21 by the Momguard test. This result was not confirmed by the karyotyping analysis. Since Momguard reports the fetal aneuploidy status as positive (high risk) or negative (low risk) only, the LabGenomics Clinical Lab reported this sample as high risk, even though the result fell in a gray zone. At the same time, the company contacted the pregnant woman who was tested, informed her of the result, and recommended karyotyping to confirm the finding.
In a study by Bianchi et al. [17] , the gray zone was defined by samples having a normalized chromosome value within 2.5-4. For these 'unclassified' samples, including 1.4% of T21 cases, 1% of T18 cases, and 0.4% of T13 cases, they did not determine the ploidy status. In the Momguard algorithm, the gray zone was defined by samples in which the ratio of similarity scores for both the center of diploidy and triploidy population in the similarity analysis results is higher than 0.9. About 0.5% of all cases fell within this marginal area for determining ploidy status. For these gray zone cases, instead of reporting them as 'unclassified', LabGenomics Clinical Lab followed the strategy outlined above.
Although the Momguard test is a highly reliable screening tool, it may have limitations in identifying some cases that are in the gray zone. To overcome this limitation, further study will be needed to improve the current algorithm. In addition, the performance of this test should be evaluated using a large number of samples from independent cohorts.
Although NIPT by MPS is now accepted as a highly reliable clinical test for detecting fetal aneuploidy, it is still considered a screening test rather than a diagnostic test [18] . Therefore, karyotyping should be recommended to women with positive Momguard results. Since sequencing technologies are rapidly improving and advanced analysis methods continue to be introduced, NIPT is expected to become the first-line of testing for all pregnant women [13] . To better assess the reliability of the Momguard test, further assessments of the Momguard test using a greater number of clinical samples will be needed. 
